Nanosonics’ Symposium at SDMS Offers Sonographers Guide to Standardizing Ultrasound Probe Reprocessing
September 25 2019 - 9:00AM
Business Wire
Highlights Innovative trophon2 for Optimized
Disinfection
Nanosonics (ASX: NAN), a leader in infection prevention
solutions, will sponsor a symposium on change management and
standardization in probe reprocessing at the Society of Diagnostic
Medical Sonography (SDMS) Annual Conference. The company will also
highlight its proprietary automated trophon®2 complete ultrasound
reprocessing system at SDMS in booth #214, Sept. 26-29, 2019.
The educational symposium, entitled “A sonographer’s guide to
standardization in ultrasound reprocessing: case studies in change
management,” will review two case studies where ultrasound probe
reprocessing was successfully standardized, with special emphasis
on challenges that arise when attempting to implement best practice
guidelines and new infection prevention processes. The session will
be led by Raleigh White, CRA, RT(R), MA, from Hutchinson Regional
Medical Center in Kansas and Robert DeJong, RDMS, RDCS, RVT, FSDMS,
FAIUM.
“Ultrasound is used in almost every healthcare setting and we
must ensure that semi-critical and critical endocavitary and
surface transducers are reprocessed following Federal guidelines to
keep patients safe from infection,” said DeJong.
“To help ensure patient safety, it’s important for sonographers
and infection preventionists to work together to standardize
ultrasound probe reprocessing workflows in their department,”
continued DeJong. “Yet, as with anything new, challenges can arise
when expanding best practices throughout a health system. The
symposium will highlight real-world case studies demonstrating how
cross-department collaboration and workflow considerations are key
to successfully implementing and standardizing new ultrasound probe
reprocessing practices.”
Nanosonics’ trophon2 is the latest innovation in automated
ultrasound probe high level disinfection (HLD). Widely considered
the standard of care, trophon2 offers a complete automated
reprocessing solution proven to be effective against a wide range
of pathogens while helping to ensure compliance with the latest
Federal guidelines.
“We’re excited to showcase our breakthrough disinfection
technology at the 2019 annual SDMS conference and also host a very
timely and important symposium on standardizing endocavitary and
surface ultrasound probe reprocessing,” said Ken Shaw, President of
North America at Nanosonics. “The adoption of trophon2 in North
America continues to expand as larger institutions implement and
standardize HLD. Just recently, a large pediatric teaching hospital
ordered 21 trophon2 systems and a nation-wide cancer center ordered
80 systems. These recent orders, along with multiple other
institutions implementing our technology, underscores the vital
importance of optimized probe decontamination throughout hospitals
and clinics.”
About trophon* Technology
Nanosonics’ trophon* technology’s high-frequency ultrasonic
vibrations generate a sonically activated, supercharged hydrogen
peroxide (H2O2) mist that inactivates drug resistant pathogens and
spores that cause sexually transmitted infections (STIs) such as
Gonorrhea, HIV and high-risk Human Papillomaviruses (HPV),1 as well
as drug resistant bacteria including MRSA. The trophon systems are
installed in more than 7,000 hospitals and facilities in North
America including all of the top 100 U.S. hospitals** and it’s
estimated that trophon technology is protecting over 70,000
patients daily from the risks of cross-contamination. The device is
compatible for use with over 1,000 surface and endocavitary
probes.
About Nanosonics
Nanosonics (ASX:NAN) is a leading medical technology company
headquartered in Sydney, Australia, with its North American
operations based in Indianapolis. Founded in 2001, the company is
one of Australia’s largest medical technology companies and a
recognized leader in its sector of the global infection control
market. More information may be found at www.nanosonics.us
*trophon [trophon EPR & trophon2]
1. Ryndock E, Robison R, Meyers C. Susceptibility of HPV16 and
18 to high level disinfectants indicated for semi-critical
ultrasound probes. J Med Virol. 2016;88(6):1076-80.
**US News and World Report.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190925005017/en/
Amy Cook amy@amcpublicrelations.net
https://www.nanosonics.us/news/media-kit/
Nanosonics (ASX:NAN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nanosonics (ASX:NAN)
Historical Stock Chart
From Dec 2023 to Dec 2024